Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers

Ipsen is hot on Marengo Therapeutics’ ability to treat “cold” tumors. The French drugmaker has agreed to pay Marengo up to $1.2 billion to access a T-cell engager platform for targeting immunologically cold tumors that are typically resistant to immunotherapies.